文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

新西兰高免疫接种人群中补充麻疹免疫接种的成本效益分析

Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
PubMed 文献 · Vaccine · 2017-08-10

新西兰在高免疫接种人群中开展麻疹补充免疫的成本效益分析。研究基于地区和国家层面免疫未暴露人数及疫苗后人群基本再生数(Rv)建模,比较补种前后疫情场景。

要点

  • 高免疫接种人群中麻疹Rv常包含或超过1(0.18-3.92)。
  • 补充接种相关人均成本需超过约66至1877美元(视情景)才不具经济效率。

核心结论

  • 即使儿童免疫接种率高,针对免疫未暴露个体的儿童期项目之外的补充免疫接种仍具有经济益处。

研究设计与样本

  • 基于地区和国家层面免疫未暴露人数及疫苗后人群基本再生数(Rv)建模,比较补种前后疫苗接种情景,对麻疹补充免疫进行成本效益分析。

主要发现

  • 高免疫接种水平下麻疹Rv常包含或超过1(0.18-3.92)。
  • 补充接种相关人均成本需超过约66至1877美元(视不同情景)才变得经济上无效率。

关键数值与推荐

  • 效益成本比分析提示常规儿童免疫之外的补充接种具有经济效率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As endemic measles is eliminated from countries through increased immunisation, the economic benefits of enhanced immunisation programs may come into question. New Zealand has suffered from outbreaks after measles introductions from abroad and we use it as a model system to understand the benefits of catch up immunisation in highly immunised populations. We provide cost-benefit analyses for measles supplementary immunisation in New Zealand. We model outbreaks based on estimates of the basic reproduction number in the vaccinated population (Rv, the number of secondary infections in a partially immunised population), based on the number of immunologically-naïve people at district and national levels, considering both pre- and post-catch up vaccination scenarios. Our analyses suggest that measles Rv often includes or exceeds one (0.18-3.92) despite high levels of population immunity. We calculate the cost of the first 187 confirmed and probable measles cases in 2014 to be over NZ$1 million (∼US$864,200) due to earnings lost, case management and hospitalization costs. The benefit-cost ratio analyses suggest additional vaccination beyond routine childhood immunisation is economically efficient. Supplemental vaccination-related costs are required to exceed approximately US$66 to US$1877 per person, depending on different scenarios, before supplemental vaccination is economically inefficient. Thus, our analysis suggests additional immunisation beyond childhood programs to target naïve individuals is economically beneficial even when childhood immunisation rates are high.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hayman DTS, Marshall JC, French NP, et al. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand. Vaccine. 2017. PMID: 28802754. doi:10.1016/j.vaccine.2017.07.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。